Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 1 of 30  
 
 
 
 
 
Evaluation of Remote Fitting in Adult and Pediatric Users of 
the HiResolution Bionic Ear System  
 
 
 
 
 
 
 
 
 
 
Reference ID: CR0121  
Version:  1.2 
Version Date: May 26, [ADDRESS_1024599] information  
 
Sponsor  Advanced Bionics LLC 
Sponsor Address:  [ADDRESS_1024600]  
 Valencia, CA  [ZIP_CODE]  
 [LOCATION_003] 
 
  

Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, [ADDRESS_1024601] Population and Selection Criteria  ................................ ................................ . 10 
7.1.1  Inclusion Criteria All Subjects  ................................ ................................ ................  10 
7.1.2  Inclusion Criteria Specifi c to ARH Group  ................................ ...............................  10 
7.1.3  Exclusion Criteria All Subjects  ................................ ................................ ...............  10 
7.2 Study Endpoints  ................................ ................................ ................................ ........  11 
7.2.1  Efficacy  ................................ ................................ ................................ .................  11 
7.2.2  Supporting data  ................................ ................................ ................................ ..... 11 
7.2.3  Safety  ................................ ................................ ................................ ....................  11 
7.3 Study Procedures  ................................ ................................ ................................ ..... 11 
7.3.1  Audiometric Measures:  ................................ ................................ ..........................  11 
7.3.2  Speech Perception Measures:  ................................ ................................ ..............  [ADDRESS_1024602] (HIPAA)  ................................ ..... 21 
11. Vulnerable Population  ................................ ................................ ................................ ... 21 
11.1 Pediatric Subjects  ................................ ................................ ................................ ..... 21 
12. Benefits and Risks  ................................ ................................ ................................ ........  22 
12.1 Benefits  ................................ ................................ ................................ .....................  22 
12.2 Risk related to Approved Products  ................................ ................................ ............  22 
12.3 Risk related to Investigational Hardware  ................................ ................................ ... 22 
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 3 of 30 12.4 Risk related to Investigational Softwa re ................................ ................................ .... 22 
13. Suspension or Premature Termination  ................................ ................................ ..........  23 
13.1 Criteria for Terminating the Study ................................ ................................ ..............  23 
13.2 Criteria for Suspending or Terminating a Study Center  ................................ .............  23 
14. Monitoring, Device Accountability and Data Management ................................ .............  23 
14.1 Monitoring Procedures  ................................ ................................ ..............................  23 
14.2 Device Accountability  ................................ ................................ ................................  24 
14.3 Data Management Procedures / Case Report Forms  ................................ ................  [ADDRESS_1024603] Retention  ................................ ................................ ..............................  26 
15.3.4  Inspection of Records  ................................ ................................ ........................  26 
15.4 Study Audits  ................................ ................................ ................................ ..............  26 
15.5 Study Funding  ................................ ................................ ................................ ...........  26 
16. Amendments and Deviations  ................................ ................................ ........................  27 
16.1 Protocol Amendments  ................................ ................................ ...............................  27 
16.2 Protocol Deviations  ................................ ................................ ................................ ... 27 
16.1 Emergency Deviations  ................................ ................................ ..............................  27 
17. Publication Policy  ................................ ................................ ................................ ..........  27 
18. Bibliography  ................................ ................................ ................................ ..................  27 
19. Study Sites, Investigato rs and External Organizations  ................................ ..................  28 
19.1 Study Sites and Investigators  ................................ ................................ ....................  28 
19.2 External Organizations  ................................ ................................ ..............................  28 
20. Revision History (if applicable)  ................................ ................................ ......................  29 
CIP Investigator Signature [CONTACT_3490]  ................................ ................................ ..............................  30 
 
 
APPENDICES  
APPENDIX A1: RISKS OF INVESTIGATIONAL HARDWARE  
APPENDIX A2: RISKS OF INVESTIGATIONAL SOFTWARE  
APPENDIX B: CASE REPORT FORMS (CRF S) 
APPENDIX C1: INFORMED CONSENT FORM (ICF)  TEMPLATE  
APPENDIX C2: ASSENT  INFORMATION  SHEET  TEMPLATE  
APPENDIX D: REPORT OF PRIOR INVESTIGATIONS / INVESTIGATOR BROCHURE  
  
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 4 of 30 1.  Synopsis  
Study Title  Evaluation of Remote Fitting in Adult and Pediatric Users of 
the HiResolution Bionic Ear System  
Sponsor  Advanced Bionics, LLC  
Investigational Device s Target CI  DS fitting software  
AB Remote  DS app 
Na√≠da CI M DS Sound Processor  
Study Design  Prospective within -subjects repeated -measures study  
Study Population  17 users  13 years or older  implanted with a HiResolution Bionic 
Ear System  
Up to 5 subjects will be enrolled in a confirmatory Aidable 
Residual Hearing (ARH) group and 1 2 subjects will be enrolled 
in an Electric Only (EO) cohort.  
Inclusion Criteria  All Subjects  ‚Ä¢ Ability to provide  Informed Consent /Assent 
‚Ä¢ 13 years of age or older  
‚Ä¢ Unilateral or bilateral user of a HiResolutionTM Bionic Ear 
System (HiRes 90KTM, HiRes 90KTM Advan tage, HiResTM 
Ultra, HiResTM Ultra 3D)  
‚Ä¢ Minimum of 6 months of CI experience with a minimum of 
1 month experience with a Na√≠da CI  or Sky CI sound 
processor  
‚Ä¢ At least moderate open -set speech recognition abilities 
(defined as speech in quiet score ‚â• 60% as as sessed at 
Visit 1) 
‚Ä¢ Minimum average  score ‚â• 3 on the Mobile Device 
Proficiency Questionnaire  (MDPQ -16) 
‚Ä¢ English language proficiency as determined by [CONTACT_3786]  
‚Ä¢ Willingness to use a BTE sound processor  for the duration 
of the study  
Inclusion Criteria Specific to ARH 
Group  ‚Ä¢ Residual low frequency hearing sensitivity (pure tone 
average of < 70 dB HL for 125, 250, and 500 Hz) and a 
severe ‚Äêto‚Äêprofound high ‚Äêfrequency sensorineural hearing 
loss (pure tone average of ‚â• 70 dB HL for 1,000, 2,000, 
3000, 4,000, a nd 8,000 Hz) in the implanted ear for 
unilaterally implanted subjects and in both ears for 
bilaterally implanted subjects  
‚Ä¢ Willingness to use an in ‚Äêcanal a coustic earhook for the 
duration of the study  
Exclusion Criteria  All Subjects  ‚Ä¢ Clinical presentation i ndicative of potential implanted 
device malfunction  
‚Ä¢ Unrealistic expectations regarding potential benefits, risks 
and limitations of the investigational device as determined 
by [CONTACT_737]  
‚Ä¢ Unwillingness or inability of subject to comply with all 
invest igational requirements as determined by [CONTACT_749246]/  Efficacy 
Objective s The primary efficacy objective is to demonstrate that speech 
recognition in quiet after remote fitting  is no worse than 
speech recognition in quiet after in-office  fitting . 
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 5 of 30 Primary Study/Efficacy Endpoint s The primary efficacy endpoint are the chronic remote  fitting 
AzBio sentence scores in quiet at Visit 3 as compared to 
chronic in -office fitting AzBio sentence scores in quiet at Visit 
2.  
Safety Objective  The sa fety objective is absence of unanticipated adverse 
device effects related to remote fitting . 
Supporting Data  ‚Ä¢ Analysis of subjective outcome measures  
‚Ä¢ Analysis of custom subject remote fitting satisfaction 
questionnaire  
‚Ä¢ Analysis of custom audiologist remot e fitting satisfaction 
questionnaire  
‚Ä¢ Analysis of subject reimbursement questionnaire  
‚Ä¢ Analysis of acute speech perception data  
‚Ä¢ Analysis of in -office fitting vs remote fitting duration  
‚Ä¢ Analysis of psychophysical data  
Study Schedule & Duration  Visit 1:  
‚Ä¢ Informed Consent /Assent  
‚Ä¢ Demographics & Audiological History  
‚Ä¢ Mobile Device Prof iciency Questionnaire  
‚Ä¢ Reimbursement Questionnaire  
‚Ä¢ Audiometric Thresholds  
‚Ä¢ Speech in Quiet, Personal  Sound  Processor  
‚Ä¢ Confirmation of Eligibility  
‚Ä¢ Na√≠da CI M DS  Sound Processor In-Office  Fitting  
‚Ä¢ Acute Speech in Quiet, Na√≠da CI M DS  Sound 
Processor  
Visit 2:  2-3 weeks after Visit 1  
‚Ä¢ Subjective Outcome Measure Questionnaire  
‚Ä¢ Chronic Speech in Quiet, Na√≠da CI M DS  Sound 
Processor  
‚Ä¢ Na√≠da CI M DS  Sound Processor Remote Fitting via 
Smart Phone App  
‚Ä¢ Acute Speech in Quiet, Na√≠da CI M DS  Sound 
Processor  
‚Ä¢ Custom Subject Remote Fitting Satisfaction 
Questionnaire  
‚Ä¢ Custom Audiologist Remote Fitting Satisfaction 
Questionnaire  
Visit 3: 2-3 weeks after Visit 2 
‚Ä¢ Subjective Outcome Measure Questionnaire  
‚Ä¢ Chronic Speech in Quiet, Na√≠da CI M DS  Sound 
Processor  
 
  
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, [ADDRESS_1024604]  
AE Adverse Event  
ARH  Aidable Residual Hearing  
BTE Behind -the-ear 
CIP Clinical Investigation Plan  
CRF Case Report Forms  
dB Decibel  
eCRF  Electronic Case Report Forms  
EDC  Electronic Data Capture  
HiResolution‚Ñ¢ (HiRes) 
Bionic Ear cochlear 
implant system  An implantable medical  device system designed to provide 
individuals who have severe -to-profound hearing loss with access 
to sound and improved perception of speech via electrical 
stimulation of the hearing nerve . It consists of (1) an externally 
worn sound processor (2) intern al implant device with receiver 
stimulator electronics package and electrode array, and (3) a 
custom fitting software used to program the external sound 
processor.  
Hz Hertz  
ICF Informed Consent Form  
IRB Institutional Review Board  
ListPlayer  ListPlayer  3.[ADDRESS_1024605] ‚Äôs sound processor  via a 
smartphone app.  
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 9 of 30   
Figure 2: Study Workflow  
  

Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 10 of 30 Adverse events (AEs) will be tracked and reported to the FDA according to the requirements of 
an IDE investigation until the s tudy is closed. The AEs will be recorded and tracked between 
completion of the informed consent form and two weeks a fter the participant completes the study .  
6. Objectives  
The primary efficacy objective is to demonstrate non-inferiority of  speech recognition  in quiet after 
remote fitting  as compared to  speech recognition in quiet after in-office  fitting.  
7. Study Protocol  
7.[ADDRESS_1024606] Population and Selection Criteria  
Advanced Bionics expects to fit up to 17 HiResolution Bionic Ear system users 13 years or 
older via remote fitting  in this clinical study across up to 5 study sites in the [LOCATION_002]. 
This study population is expected to be representative of the target population for remote 
fitting. An individual is considered to be enrolled as a study participant onc e the informed 
consent document has been signed and dated. It is anticipated that more than 17  subjects 
will be enrolled in the study as some may not meet the inclusion / exclusion criter ia. Prior to 
recruitment, written approval of the investigational pla n and informed consent form will be 
obtained from the FDA and associated participating study center Institutional Review Boards 
(IRB). Study participants are required to meet the study in clusion criteria as determined by 
[CONTACT_079]. Dependi ng on the outcome of their audiogram, eligible subjects 
will be enrolled for aidable residual hearing (ARH) fitting with an acoustic earhook . 
Unilaterally implanted s ubjects not meeting A RH fitting criteria will be enrolled for electric 
only (EO) fitting.  Bilaterally implanted subjects meeting ARH criteria only in one ear will be 
screen failed.  
Enrollment in the study is expected to occur over a period of  approximately  6 months. 
Subjects m eeting inclusion criteria will participate in 3 study visits over app roximately 4-6 
weeks.  
7.1.1  Inclusion Criteria All Subjects  
‚Ä¢ Ability to provide Informed Consent /Assent  
‚Ä¢ 13 years of age or older  
‚Ä¢ Unilateral or bilateral user of a HiResolutionTM Bionic Ear System (HiRes 
90KTM, HiRes 90KTM Advantage, HiResTM Ultra, HiResTM Ultra 3D) 
‚Ä¢ Minimum of 6 months of CI experience with a minimum of 1 month experience 
with a Na√≠da CI  or Sky CI  sound processor  
‚Ä¢ At least moderate open -set speech recognition abili ties (defined as speech in 
quiet score ‚â• 60% as assessed at Visit  1) 
‚Ä¢ Minimum average score ‚â• 3 on the Mobile Device Proficiency Questionnaire 
(MDPQ -16) 
‚Ä¢ English language proficiency as determined by [CONTACT_737]  
‚Ä¢ Willingness to use a BTE sound processor  for the duration of the study  
7.1.2  Inclusion Criteria Specific to ARH Group  
‚Ä¢ Residual low f requency hearing sensitivity (pure tone average of < 70 dB HL for 
125, 250, and 500 Hz) and a severe ‚Äêto‚Äêprofound high ‚Äêfrequency se nsorineural 
hearing loss (pure tone average of ‚â• 70 dB HL for 1,000, 2,000, 3000, 4,000, 
and 8,000 Hz) in the implanted ear for unilaterally implanted subjects and in 
both ears for bilaterally implanted subjects  
‚Ä¢ Willingness to use an in ‚Äêcanal acoustic earh ook for the duration of the study  
7.1.3  Exclusion Criteria  All Subjects  
‚Ä¢ Clinical presentation indicative of potential device malfunc tion 
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 11 of 30 ‚Ä¢ Unrealistic expectations regarding potential benefits, risks and limitations of the 
investigational device as determined by [CONTACT_737]  
‚Ä¢ Unwillingness or inability of subject to comply with all investigational 
requirements as determined by [CONTACT_14520]  
7.2 Study Endpoints  
7.2.1  Efficacy  
The purpose of the proposed study is to evaluate speech performance efficacy 
objectives. The primary  efficacy endpoint s are chronic remote fitting AzBio sentence 
scores in quiet at Visit 3 as compared to chronic in -office AzBio sentence scores in 
quiet at Visit 2.  
7.2.2  Supporting data  
In addition  to acute speech performance , psychophysical data and fitting durations , 
information from subjective questionnaires will be collected as supporting data:  
‚Ä¢ Information regarding study pa rticipants experience during fitting sessions will 
be collected via a Subject Remote Fitting Satisfaction Questionnaire.  
‚Ä¢ Information regarding study participants listening experience during the chronic 
periods will be collecte d via a SSQ -12 questionnaire.  
‚Ä¢ Information regarding study participants reimbursement situation  will be 
collected via a Reimbursement  Questionnaire.  
‚Ä¢ Information regarding investigators‚Äô experience during fitting sessions will be 
collected via an Audiologist  Remote Fitting Satisfaction Questionnaire.  
‚Ä¢ Information regarding acute speech perception will be collected in  form of AzBio 
sentence scores collected immediately after in -office and remote fitting, 
respectively.  
‚Ä¢ Information regarding duration of in-office and remote fitting duration s will be 
collected during the fitting sessions.  
‚Ä¢ Information regarding  psychophysical data  will be collected during the fitting 
sessions.  
7.2.[ADDRESS_1024607] that they do not bias data integrity. No study procedures will be performed 
by [CONTACT_749247].  
7.3.1  Audiometric Measures:  
Unaided air conduction hearing thresholds (in dB HL) will be measured for the 
implanted ear(s) using the  centers calib rated audiometer and  standard audiometric 
technique for pure -tone air conduction testing.  
Unaided air conduction thresholds using insert earphones at octave and inter -octave 
frequencies will be obtained (125, 250, 500, 1000, 2000, 3000, 4000 and 8000 Hz) . 
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 12 of 30 7.3.2  Speech Perception Measures:  
All speech perception testing will be conducted using recorded stimuli presented 
from a single loudspeaker in , at a minimum , a single -walled sound booth capable of 
accommodating  the calibrated speaker orientation. Soundfield le vels will be 
calibrated to [ADDRESS_1024608]‚Äôs head (one meter from loudspeaker).  
Speech per ception measures in the soundfield are to be administered unilaterally  for 
unilaterally implanted subje cts and bilaterally for bilaterally implanted subjects  via a 
loudspeaker at 0¬∞ azimuth at a distance of one meter from the subject. Speech 
signals will b e presented at 60 dBA.  
Devices will be removed from the non ‚Äêtest ear (if necessary)  for unilaterally 
implanted subjects  and foam plugs will be used to isolate the test ear  for unilateral 
users .  
7.3.[ADDRESS_1024609] (Spahr et al. , 2012) is a validated test of open -set 
sentence recognition ab ility. The test will be administered in quiet at 60 dBA (target 
0¬∞ azimuth). The test is scored as total number of words correct which will be 
expressed for reporting as percentage correct. The  sentence tokens include both 
male and female speakers.  
Acute AzBio sentence testing will be performed immediately following in -office and 
remote fitting sessions, respectively. Chronic AzBio sentence testing will performed 
at the beginning of each follow -up visit.  
7.3.4  Questionnaires  
Subjects will be completing  a Mobile Device Prof iciency Questionnaire (MDPQ -16), 
subjective outcome measures questionnaire s (SSQ -12), a reimbursement 
questionnaire and a custom remote fitting satisfaction questionnaire. In additio n, 
audiologists will be completing a custom remote fitting sati sfaction questionnaire.  
Questionnaires may  be comp leted on paper or electronically  in the EDC system . 
7.4 Study Visits and Visit Windows  
7.4.1  Schedule of Events  
Procedure  
Visit 1  
Visit 2  
Visit 3 
Informed Consent /Assent  ÔÅ°
Demographics & Audiological History  ÔÅ°
Mobile Device Proficiency Questionnaire  ÔÅ°
Reimbursement Questionnaire  ÔÅ°
Audiometric Thresholds  ÔÅ°
AzBio in Quiet, Personal Sound Processor  ÔÅ°
Confirmation of Eligibility  ÔÅ°
Na√≠da CI M DS  Sound Proce ssor In -Office Fitting  ÔÅ°
Na√≠da CI M DS  Sound Processor Remote Fitting via Smart 
Phone App  ÔÅ°
Acute AzBio  in Quiet, Na√≠da CI M DS  Sound Processor  ÔÅ°ÔÅ°
Chronic AzBio  in Quiet, Na√≠da CI M DS  Sound Processor  ÔÅ°ÔÅ°
Subjective Outcome Measure Questionnaire  (SSQ -12) ÔÅ°ÔÅ°
Custom Subject Remote Fitting Satisfaction Questionnaire  ÔÅ°&
Custom Audiologist Remote Fitting Satisfaction Questionnaire  ÔÅ°&
Adverse Event Assessment  ÔÅ°ÔÅ°ÔÅ°
Device Accountability  ÔÅ°ÔÅ°ÔÅ°
& Only if remote fitting was successfully complet ed 
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, [ADDRESS_1024610]‚Äôs office.  
‚Ä¢ After informed consent /assent , subject‚Äôs demographics and hearing history will 
be captured.  
‚Ä¢ Subjects‚Äô technical competency will be determined using the Mobile Device 
Proficiency (MDPQ -16) questionnaire  and subjects will complete a Reimbursement 
Questionnaire.  
‚Ä¢ Speech perception in quiet will be tested using the subject‚Äôs personal sound 
processor  to determi ne eligibility for the study.  
‚Ä¢ Audiometric thresholds are used to determine whether subje cts are considered 
to have aidable residual hearing (ARH) . Subjects no t meeting the ARH criteria 
will be fitted under the electric -only criteria (EO).  Audiometric thresholds will be 
determined for the implanted ear only for unilaterally implanted subjects and for 
both ears individually for bilaterally implanted subjects.  
‚û¢ Bilateral subjects meeting the ARH inclusion criteria in both ears will be 
enrolled in the ARH group.  Bilateral subjects meeting ARH criteria in only 
one ear will be screen failed.  
‚Ä¢ Subjects  who meet inclusion and do not meet exclusion criteria  are then fit wi th 
a Na√≠da CI M DS  sound processor in the audiologist‚Äôs office. Unilateral ARH 
subjects will be fitted with an acoustic earhook and EO subjects will be fitted with 
a T-mic. Bilateral sub jects meeting the ARH criteria will be fitted with an acoustic 
earhook in both ears. Fitting parameters on the Na√≠da CI M DS  sound processor 
shou ld mimic the parameters on the subject‚Äôs personal sound processor  as 
closely as possible and be adjusted for co mfort and sound quality as needed. 
Program settings will include two programs, one AutoSense OS program with 
and a second manually selected Calm situation  program . This will be considered 
the in -office fitting.  
‚Ä¢ Acute s peech perception in quiet is performed  to confirm the  in-office  fitting on 
the Na√≠da CI M DS  sound processor.  
‚Ä¢ Adverse events  and device observations  are collected, as needed, and device 
accountability is performed.  
‚Ä¢ Following the visit, the subject will test the Na√≠da CI M DS  sound processor 
chronically for 2 -3 weeks during their day -to-day activities.  
7.4.3  Visit 2  
Visit 2 will occur 2 -3 weeks after Visit 1 .  
‚Ä¢ The visit will start at the audiologist‚Äôs office with subjects completing a subjective 
outcome measures questionnaire.  
‚Ä¢ Chronic  speech perc eption in quiet will be tested using AzBio sentences.  
‚Ä¢ In addition,  the audiologist will introduce the remote fitti ng application to the 
subject and will pair the smartphone with the subject‚Äôs Na√≠da CI M DS  sound 
processor. For the purposes of the study, a ded icated fitting smartphone will be 
used that is only used for remote fitting.  
‚Ä¢ The subject will then move to the  remote fitting location. The audiologist will 
initiate the remote fi tting session through Target CI DS, and the subject will open 
the applicatio n on the remote fitting smartphone. Both parties will engage 
verbally to ensure audibility and visualization  via smartphone video  during the 
call. The audiologist then remotely connects to the subject‚Äôs sound processor  to 
begin the fitting session. The fit ting will include measurement of impedances,  
measurement of electrode -specific neural response imagin g (NRI),  programming  
of M levels, and live speech stimulation to confirm acceptability of adjustments. 
Fittings for A HR subjects will include a review of a coustic and electric cutoff 
frequencies and gains at 65 dB. Additional adjustments may be made as needed 
to ensure comfort and clarity of the Map  and to ensure acceptability of the fitting 
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, [ADDRESS_1024611]‚Äôs chronic wear period.  The audiologist and subje ct will then 
confirm the completion of the fitting and both parties close their respective 
remote  fitting session applications.  
‚û¢ Should technical issues occur during the remote fitting session, the 
audiologist will first try to mitigate the issues, for exa mple by [CONTACT_749248] a different location  in 
case of poor connection.  
‚û¢ The audiologist will re -schedule the remote fitting session s hould the 
remote app fitting not be completed because  technical iss ues could not be 
mitigated  during the session . Adverse events  and/or device observations 
are collected and device accountability is performed, as needed.  
‚û¢ If remote fitting cannot be completed due to non -technical reasons (e.g. 
subject was not able to suffi ciently communicate with the audiologist via 
the app), the subject will be exited from the study . Reasons for non -
completion of the remote fitting will be documented. Adverse eve nts and/or 
device observations are collected and device accountability is perf ormed.  
‚Ä¢ After the remote fitting session  is successfully completed , the subject will re join 
the audiologist in person for  acute speech perception in quiet to confirm the 
remote fi tting on the Na√≠da CI M  DS sound processor.  
‚Ä¢ In addition, the audiologist and the subject each will complete a custom remote 
fitting satisfaction questionnaire.  
‚Ä¢ Adverse events and device observations are collected and device accountability 
is performed, as needed.  
‚Ä¢ Following the visit, the subject will test the r emotely -fitted Na√≠da  CI M DS  sound 
processor chronically for 2 -3 weeks during their day -to-day activities.  
7.4.4  Visit 3 
Visit 3  will occur 2 -3 weeks after  the Visit 2 . 
‚Ä¢ This visit is performed at the audiologist‚Äôs office and begins with subjects 
completing a subjective outcome meas ures questionnaire.  
‚Ä¢ In addition, chronic speech perception in quiet will be tested.  
‚Ä¢ Adverse events  and device observations  are collected, as needed, and device 
accountability is performed.  
‚Ä¢ The subject will then return the Na√≠da CI M DS  sound processor an d return to 
using their personal sound processor . Standard clinical follow -up is 
recommended after subjects exit the study.  
7.5 Withdrawal of Subje cts 
Study participants may withdraw from the study at any time, with or without reason, and 
without prejudice to further treatment. The study site Investigator(s) and/or study Sponsor 
have the right to discontinue study participants. Participants can be discontinued for the 
following reasons:  
‚Ä¢ Voluntary withdrawal of consent made by [CONTACT_2299]  
‚Ä¢ A safety concern id entified by [CONTACT_079], the Sponsor, or any third party  
‚Ä¢ Inability of the subject to perform the tasks nec essary to provide usable data for the 
study  
‚Ä¢ Failure to respond after three documented attempts to contact [CONTACT_423]  (lost to follow -
up). Potential reasons will be documented.  
Once a subject is withdrawn or discontinued they will be required to return the Na√≠da CI M 
DS sound processor utilized for the study. Subjects  who withdraw or who are discontinued 
from the study will be reported ac cordingly to the Institutional Review Boar d. If a subject 
was discontinued because of a device -related adverse event or serious adverse event 
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 16 of 30 than -10 percentage p oints  for AzBio in quiet mode, which will support that the 
Investigational condition is non -inferio r to the Control condition. Previous data supported 
6.24% SD for the primary efficacy endpoint . As shown in Table 1 below,  with a sample size 
of 8 complete p airs there is 97% power to rule out a -10% null hypothesis supporting non -
inferiority for a one -sided 2.5% test with statistical significance .  
Table 1: Paired t -tests to reject the null hypotheses for non -inferiority and superiority  
 Non-
Inferiority  
Test significance level,  ÔÅ° 0.[ADDRESS_1024612]?  1 
Null hypothesis mean difference,  ÔÅ≠0 -10 
Alternative mean difference,  ÔÅ≠A 0 
Paired SD,  ÔÅ≥ 6.[ADDRESS_1024613] size,  ÔÅ§ = |ÔÅ≠A - ÔÅ≠0| / ÔÅ≥ 1.603  
Power (%)  97 
N 8 
These calculations are based on the T -distribution non -centrality facto r as follows:  
( )
ÔÅ≥ÔÅ≠ ÔÅ≠0
,‚àí=ÔÅÑnTNCFn
 
observed based on the non-centrality factor:  
ùëÉùëúùë§ùëíùëü = ùëáùëõ‚àí1(ùëáùëõ‚àí1‚àí1(0.975 ),ùëõ‚àí1,ùõø= ùëáùëõ,ùëÅùê∂ùêπ) 
The above sample size calculation provide s the minimum sample size for the EO cohort. In 
addition, 5 ARH subjects will be enrolled in the study to provide confirmatory data for the 
electric and acoustic fitting mode  for subjects wearing an acoustic earhook . The incidence 
of acoustic earhook use am ong Advanced Bionics recipi[INVESTIGATOR_749240], less than 2.5% of US 
recipi[INVESTIGATOR_840]. As such, a confirmatory sample of 5 subjects is considered sufficient  in order to 
provide clinical data via  descriptive sta tistics . Outcomes after remote fitting are expected to 
be si milar between the EO cohort and the ARH group.  The total sample  size was expanded 
to 17 (12 EO and 5 ARH) as the expected dropout rate due to withdrawals  or lost to follow -
up is not expected to exceed [ADDRESS_1024614] event rate was calculated in order to provide c omplication rates. If no events are 
observed in 17 subjects, then 16.2% is the upper bound for a one -sided 95% confidence 
interval on this event rate.  
8.2 Data Analyses  
Subjects will  be analyzed separate ly for the AzBio in quiet mode for remote fitting 
(Inves tigational) and for the in -office fitting (Control) as well as the paired difference . All 
enrolled subjects that meet the inclusion / exclusion criteria will be included in the in tent-to-
treat (ITT) population. The analysis will be repeated for the per -protocol (PP) population 
excluding subjects with major protocol deviations. Protocol deviations will be classified as 
major if they affect data in tegrity  for the primary endpoint  or subject safety  as defined in 
Table 2  below. 
  
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 17 of 30 Table 2: Major Protocol Deviations  
Protocol deviations 
affecting data integrity of 
the primary endpoint  Chronic speech perception testing not performed in, at a minimum, 
a single -walled sound booth . 
Chronic speech perception testing performed withou t prior 
calibration of sound field levels to 74dB SPL . 
Chronic speech perception testing not performed  at 0¬∞ azimuth . 
Chronic speech perception testing not performed  at a distance of 
one meter from the subject . 
Chronic speech perception testing not p erformed  with s peech 
signals presented at 60 dBA . 
Chronic speech perception testing performed  without removing 
hearing devices  (if necessary)  from contralateral ear for unilaterally 
implanted subjects.  
Chronic speech perception testing performed  withou t using foam 
plugs in contralateral ear for unilaterally implanted subjects  with 
residual hearing in the contralateral ear . 
Chronic speech perception testing not performed  using two lists of 
AzBio sentences.  
Chronic speech perception testing not perfor med bilaterally for 
bilaterally implanted subjects.  
Protocol deviations 
affecting subject safety  Protocol deviations that result in a serious adverse event  
8.2.1  Efficacy Endpoints  
The primary efficacy endpoint is chronic  speech recognition using  AzBio  senten ce 
tests  in quiet for  remote  fitting  vs. in-office fitting . Non-inferiority analysis will be 
based on a paired t -tests looking at the  mean  difference in scores (D) calculated 
from the chronic remote fitting speech perception testing (investigational ) minus  the 
chronic in -office fitting speech perception scores. Unilateral and bilateral 
involvement will be additionally considered in two separate manners for the primary 
effectiveness analysis  endpoint  to assess t he remote vs local difference. First, the 
unila teral and the bilateral subjects will be analyzed as separa te subgroups . Second, 
a linear regression analysis for the paired difference will include a covariate for 
whether the subject is unilateral (reference group) or bilateral in order to evaluate 
the laterality effect.  Clinical  significa nce is defined as ruling out a -[ADDRESS_1024615] ing the null hypotheses, indicating that  the means of the 
paired differences ar e greater  than ‚Äì [ADDRESS_1024616] protocol . Multiple imputation will be used 
to analyze the primary  efficacy endpoint ( SAS PROC MIANALYZE; Little and Rubin 
[2002] ). Subject values wi ll be imputed using observed test scores and  selected 
baseline variables.  
8.2.2  Supporting Data  
The following suppor ting data will also be evaluated using descriptive statistics:   
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 18 of 30 ‚Ä¢ subjective outcome measures  
‚Ä¢ custom subject remote fitting satisfaction questionn aire 
‚Ä¢ custom audiologist remote fitting satisfaction questionnaire  
‚Ä¢ subject reimbursement questionnaire  
‚Ä¢ acute speech perception data  
‚Ä¢ in-office fitting vs remote fit ting duration  
‚Ä¢ psychophysical data  
‚Ä¢ duration of in -office vs remote fitting . 
8.2.3  Analyses of Individ ual Results  
A critical difference score will be used to determine whether individual subjects 
demonstrate a significant decrease in performance between the Inves tigational 
(remote fitting ) and Control ( in-office fitting ) conditions. Specifically, the crit erion 
value for the critical difference score will be based upon the test -retest variance on 
the AzBio test. Gifford (2008) provided a set of data on [ADDRESS_1024617] deviation œÉ of 3.8%. The critical difference score can be  
computed based on the assumption that (1) the difference scores have a normal 
distribution, a nd (2) the difference scores are deemed significant if, under the null 
hypothesis, the probability of the difference score exceeding the critical score is 1%. 
Under these assumptions, the critical improvement (or decrement) score CS is equal 
to: 
CS = œÉ * b 
In the above equation, b = 2.33, the percentile of the normal curve corresponding to 
the desired values of ÔÅ° = 0.01, one -tailed test. Using Gifford‚Äôs œÉ value, the critical 
difference score for AzBio sentences is 8.9%.  
The number and percentage of subjec ts exceeding, within, and below the critical 
difference (Investigational - Control) score will be tabulated. The shift will be 
summarized for both the Experimental and Control results indicating improved, the 
same, or deteriorated. Further the difference b etween the two strategies will be 
evaluated and classified as better for the Experimental strategy, the same for both 
strategies, or better for the Control strategy. A two -sided exact binomial test will be 
used to evaluate the null hypothesis that the dist ribution of subjects showing a 
performance difference (Investigational is better or Control is better) is  distributed 
equally. This analysis will provide an additional indication of the efficacy of remote 
fitting  relative to in-office fitting  based upon in dividual data.  
8.2.[ADDRESS_1024618]  demographics and study results will be presented  descriptively  
to assess site  heterogenity . 
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 19 of 30 9. Adverse Events and Device Deficiencies  
An adverse event (AE) is defined as any undesirable clinical occurrence experienced by a study 
subject when using the HiResolution System or when undergoing research procedures, whether 
or not the AE is co nsidered to be device -related. The definition of an AE also includes any event 
related to a ny study procedures o r to any underlying medical condition present at baseline that 
increases  in severity during the study. An underlying medical condition that was present at the 
time of enrollment will not be reported as an AE, but any increase in severi ty during the study w ill 
be reported as an AE .  
All device -related and non -device -related adverse events (AEs) will be tracked and reported 
accordingly throughout the study as defined above in the investigational plan and in accordance 
with require ments of  an IDE investigation . The AEs will be recorded and tracked between 
completion of the informed consent form (signed and dated) and two weeks after the participant‚Äôs 
last study visit. The number and percent of all subjects experiencing adverse events will b e 
summarized by [CONTACT_24975],  status and frequency of event. Adverse Events will be recorded and will 
include but are not limited to the following information [refer to Appendix B for Case Report Forms 
(CRFs)]:  
9.1 Adverse Event Definitions and Classifications  
9.1.1  Serious  Adverse Event  
A seri ous adverse event (SAE) is an event that: a) led to a death, or b) led to a 
serious deterioration in the health of the subject that:  
‚Ä¢ resulted in a life -threatening illness or injury,  
‚Ä¢ resulted in a permanent impairment of a body struct ure or of a body func tion, 
‚Ä¢ required inpatient hospi[INVESTIGATOR_1081],  
‚Ä¢ resulted in medical or surgical intervention to prevent permanent impairment to 
body structure or a body function, or  
‚Ä¢ led to fetal distress, fetal de ath or a congenital a bnormality or birth defect.  
9.1.[ADDRESS_1024619] (ADE) is any untoward and unintended  response to a 
medical device. A serious adverse device effect (SADE) is an event related to the 
device that re sulted in any of the consequences characteristic of a serious adverse 
event (SAE) or that might have led to any of the consequences if suitable action had 
not been taken or interventions had not been made or if circumstances ha d been 
less opportune.  
9.1.[ADDRESS_1024620] (UADE) is any serious adverse effect on 
health or safety; any life threatening problem or death caused by, or associated with, 
a device, if that effect, probl em, or death was not previous ly identified in nature, 
severity, or degree of incidence in the investigational plan or application; or any other 
unanticipated serious problem associated with a device that relates to the rights, 
safety, or welfare of subject s. 
9.2 Adverse Event Reporting  
All adverse events and adverse device effects, serious and non -serious, will be recorded on 
the Adverse Event Report Case Report Form [CRF] (see Appendix B for all CRFs). 
Information to be recorded on the CRF should include, but is not limited to:  
‚Ä¢ Date of on set of the adverse event  
‚Ä¢ Description of the event, duration and severity  
‚Ä¢ Seriousness  
‚Ä¢ Relatedness  
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 20 of 30 ‚Ä¢ Treatment/Intervention ‚Äì course of action taken  
‚Ä¢ Outcome/Status (Resolved, Improved, Stable, Worse, Unchanged) . In case of an SAE, 
the subject must be followed until the serious adverse device effect is resolved or no 
reasonable improvement is expected .  
Investigators should immediately report any SAEs, SADEs and UADEs to Advanced Bionics 
at ClinicalResea [EMAIL_14306] . Evaluation of any SAE, SADE, or UA DE will 
be conducted promptly. Confirmed UADEs will be reported to the FDA according to 21 CFR 
Part 812.150(b) (1) within [ADDRESS_1024621] presents an unreasonable risk to subjects, this study, or those parts of the study 
presenting that risk, will be terminated  no la ter than 5 working days after the de termination 
is made and no later than 15 working days after Advanced Bionics/Clinical Research first 
received notice of the event.  
9.3 Anticipated Adverse Events  
The risks associated with the investigational products include  but are not limited to:  
‚Ä¢ There is a possibility that speech and environmental sounds may sound different or 
louder than what the subjects are accustomed to hearing or that subjects may not like 
the sound quality of the study  sound processor  used in the study . This risk occurs with  
all change s to sound -processing, and subjects should be advised of this possibility. If a 
subject cannot tolerate using the study sound  processor or does not like the sound 
quality, they can return to using their own sound processor  with their baseline 
programming. In this event, the subject will be withdrawn from the study.  
‚Ä¢ Subjects may experience some overly loud sounds that result in discomfort. If such loud 
sounds occur, they can be stopped immediately by [CONTACT_749249][INVESTIGATOR_235712]/or the 
entire extern al device.  
‚Ä¢ Subjects may experience neural tissue damage in the event of chronic overstimulation.  
‚Ä¢ There is risk of facial nerve stimulation. This risk can be mitigated through 
reprogramming of the device.  
‚Ä¢ Subjects may experience intermittent sound or short -term loss of functionality while 
wearing the device or while being programmed. The intermittency can be eliminated by 
[CONTACT_749250][INVESTIGATOR_13959], reprogramming the sound processor , or exchanging the sound 
processor . 
‚Ä¢ Subjects may have permanent residual acoust ic or natur al hearing damage due to 
excessive acoustic power.  
‚Ä¢ Subjects may experience skin or tissue irritation because of the device materials or the 
equipment may overheat or otherwise malfunction, causing tissue damage.  
‚Ä¢ Subjects will be exposed to sma ll parts th at pose a choking hazard. Care should be 
taken to avoid choking and the outcomes of choking, such as endoscopic surgery or 
death.  
‚Ä¢ Exposure to electromagnetic emissions from the device (external sound processor, 
internal device) may adversely in terfere wit h other electronic medical devices  
‚Ä¢ Subjects should only use accessories compatible or designed for the study  sound 
processor  (such as the battery chargers) in order to avoid electric shock.  
‚Ä¢ Static electricity can potentially damage sensitive electronic com ponents such as the 
ones used in the cochlear implant system.  
A complete listing of the risks can be found in Appendix A; all risks listed are considered 
anticipated Adverse Events. Risks are minimized by [CONTACT_749251]. At any time, subjects may discontinue use of the study sound 
processor , and return to using their own sound process or and baseline program. If subjects 
stop using the study  sound processor  during the study, they will be withdrawn from the 
study.  
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 21 of 30 In all case, the event(s) will be recorded and the incidence of such events reported as part 
of the results analysis.  
9.4 Device Deficiencies  
Events that involve a device issue or observation need to be reported as Device 
Observations and Deficiencies (DODs) vi a the Electronic Data Capture system. Adverse 
event  reporting takes precedent over DOD reporting. Therefore it is not necess ary to report 
an event as a  DOD if it has already been reported as an AE because it led to a medical 
occurrence for the subject.  
10. Informed Consent Process  
A study site‚Äôs Informed Consent Form template  and Informed Assent Form template  with center 
specific/required language must be provided to Advanced Bionics for approval prior to submission 
to the Ins titutional Review Board (IRB). Adva nced Bionics will provide an informed consent and 
informed assent template and assistance in adapting th e template s to conform to local 
requirements (Appendix C). All informed consent  and informed assent  documents and patient 
information sheets must contai n the minimum elements as mandated by [CONTACT_8415] (21 CFR Part 50) 
and will  be subject to approval by [CONTACT_749252] .  
Before enrollment, the study will be explained to eac h prospective study candidate. Candidates 
will be asked to read the app roved informed consent form and given the  opportunity to ask 
questi ons. Once all questions have been answered and the Investigator is assured that the 
individual understands the implications of participating in the study, the subject will be asked to 
sign and d ate the informed consent form. The Investigator will provide a copy of the informed 
consent form to each subject.  The process for pediatric subjects is described in section 11.  
Study subjects will receive a small payment at each visit for their time a nd effort and will be 
reimbursed for travel related cost.  
If an amendment to the protocol changes the scope or activities associated with a subject‚Äôs 
participation, or increases the potential risk to the subject, the informed consent  and informed 
assent  forms must be revised and submitted to the IRB for review an d approval. Actively enrolled 
study participants are re -consented accordingly if affected by [CONTACT_29991]. The revised 
informed consent  and informed assent  forms must be used to obtain consent from  any new 
subject who is enrolled in the study after the da te of the approval of the amendment.  
10.[ADDRESS_1024622] (HIPAA)  
All subjects must sign a HIPAA authorization form prior to participation in the study. The 
Investigat or will prepare the HIPAA authorization form according to their institution‚Äôs policy 
and provide it to Advanced Bionics for approval. Advanced Bionics will provide a template 
HIPAA research authorization form for reference. All subjects must sign the autho rization 
form prior to participation in the study if the H IPAA information is not included in the 
institution‚Äôs informed consent.  
11. Vulnerable Population  
11.1 Pediatric  Subjects  
HiResolution Bionic Ear System is approved for use in pediatric patients between 12 m onths 
and 17 years with profound  bilateral sensorineural hearing loss , and in adults 18 years and 
up with severe to profound bilateral sensorineural hearing loss . Advanced Bionics 
recognizes that the benefit/risk profiles  of remote fitting  could be differe nt among patients of 
different ag e ranges, especially with regards to pediatric patients at very young ages. 
Therefore remote fitting is intended to be used in follow -up programming of Advanced 
Bionics cochlear implant recipi[INVESTIGATOR_840] 13 years and older who are  able to self -report a 
preference  for different fitting characteristics (e.g., mappi[INVESTIGATOR_749241]).  The benefits of 
remote fitting are the same for pediatric  subjects as for adults (see section 12.1). While 
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 22 of 30 audiological care for pediatric patients in this  age range is similar to adults, it is stil l important 
to ensure that remote fitting is a suitable option for these pediatric age group. Therefore 
Advanced Bionics is planning to enroll pediatric subjects 13 years of age and older in this 
study . After info rmed consent is obtained from a parent / legal guardian , informed assent 
will be obtained from the pediatric subject. The informed assent process will closely follow 
the informed consent process for adult subjects.   
Governing IRBs will give special conside ration to protecting the welfare of vulnerable 
subjects  per federal regulations. The study will only enroll pediatric  subjects who have the 
ability to understand the requirements of the study and who are able to communicate 
untoward experience or preferenc e for diff erent fitting characteristics , as determined by [CONTACT_3786] . After exiting the study, pediatric subjects will return to using their personal 
sound processor  and will be followed per standard clinical care.  
12. Benefits and Risks  
12.[ADDRESS_1024623] s‚Äô 
instructions for use.  
12.3 Risk related to Investigational Hardware  
 
(  The risk analysis contains the 
determination th at the benefit provided by [CONTACT_749253] -case outweighs any residual risk. The 
full report is presented in Appendix A.  
12.4 Risk related to Investigational Software  
 
 
 The risk analysis contains the determination that the benefit provided by [CONTACT_749254]-case outweighs any residual risk. The full report is presented in Appendix A.  
In addition, the following risks are related to remote fitting:  
‚Ä¢  
 
 
  
 
 
  
 
 
 

Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, 2021                    Confidential  
 Page 23 of 30 ‚Ä¢  
 
13. Suspension or Premature Termination  
13.1 Criteria for Terminating the Study  
Advanced Bionics reserves the right to te rminate the study at any time. However, this right 
will be exercised only for valid scientific or busines s reasons, or because of issues related 
to protection of research subjects.  Investigators and IRBs will be notified in writi ng in the 
event of termination.  If the study is prematurely terminated o r suspen ded, the Principal 
Investigator [INVESTIGATOR_749242], provide the reason(s) for the termination 
or suspension and changes to the study v isit schedule, as applicable.  Any subjects that 
have not completed the study at the time of t ermination will be required to return the study 
sound proces sor and will resume using their personal sound processor .  
No special follow -up procedures are required following the end or termination of the study 
as subject will be returning the study Na√≠da CI M DS  sound processor  and returning to using 
their personal  sound processor . The same applies to subjects who withdraw consent or are 
lost to follow -up. Should the study be temporarily halted, subjects will be asked to return the 
study Na√≠da CI M DS  sound  processor  until a determination is made whether the study w ill 
continue.  
13.2 Criteria for Suspending or Terminating a Study Center  
After the study begins, Advanced Bionics reserves the right to suspend  enrollment of 
subjects at a study center  or terminate a study center ‚Äôs participation in the study  at any time 
if (1)  no subjects have been enrolled, (2) the center has multiple or severe unjustified 
protocol violations or (3) the center fails to follow re medial actions for protocol violations.  
Any subjects enrolled at this center that have not completed the study at the  time of 
termination will be required to return the study sound processor  and will resume using their 
personal sound processor . 
Possible re asons for suspending or terminating a center include:  
‚Ä¢ Investigator non -compliance.  
‚Ä¢ Repeated failure to complete or su bmit eCRFs in a timely manner.  
‚Ä¢ Failure to obtain written informed consent from each subject.  
‚Ä¢ Failure to report an SAE or UADE to Advanced Bionics within [ADDRESS_1024624] been trained on the study investigational plan, mo nitoring procedures, and 

Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, [ADDRESS_1024625] operating procedures based on Good Clinical Practice and other applicable  
Federal regulations.  
The following or otherwise designated Advanced Bionics Clinical Research Department 
Personnel will be responsible for conductin g the study monitoring:  
 
Address:  
Advanced Bionics, LLC  
Clinical Research Department  
[ADDRESS_1024626]  
Valencia, CA [ZIP_CODE]  
 
14.2 Device Accountability  
Participants will be fitted with a Na√≠da CI M DS  sound processor  at their participating study 
center . The investigational devices will be shipped with the following label: "CAUTION --
Investigational device. Limited by [CONTACT_4496] (or [LOCATION_002]) law to investigational use." The 
serial numbers for the Na√≠da CI M DS  sound processor s will be logged at the stu dy site for 
each study participant.  
The statement "CAUTION --Investigational device. Limited by [CONTACT_4496] (or [LOCATION_002]) law 
to invest igational use" will be placed onto the study  laptop with the investigational Target CI 
DS software  as well as the smartp hone s programmed with the investigational remote fitting 
app.  
Advanced Bionics will track all investigational study laptops and smartph ones  sent to study 
centers using the  manufacturer  serial numbers . Study centers will return the investigational 
devices to Advanced Bionics after all subjects have been exited from the study  and 
Advanced Bionics will track the receipt of those devices . 
14.3 Data Management Procedures / Case Report Forms  
Advanced Bionics will provide study centers with acc ess to a study specific Electronic Data 
Capture (EDC) system meeting [ADDRESS_1024627] be submitted according to protocol requirements  for all enrolled subjects  as soon 
as possible after the visit . Electronic Case Report Forms (eCRFs) provided for this study 
will be used to submit data (Append ix B). Each subject will be assigned a unique identifier 
at the time of the first visit, wh ich w ill be used on all eCRFs.  
The EDC database will be locked prior to analysis of the data and data will be retained 
indefinitely. Study Investigators will be pro vided with an electronic copy of the EDC database 
containing only the data from their subjects.  

Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, [ADDRESS_1024628] agree that the study will be conducted according to the protocol, the 
principles of Good Clinical P ractices (GCPs) outlined in 21 CFR parts 50, 56, and 812, the 
World Medical Associatio n Declaration of Helsinki, and internal Standar d Operating 
Procedures (SOPs). In addition, the Investigator will conduct all aspects of this study in 
accordance with FDA and local regulations  as well as ISO [ADDRESS_1024629] recruitment materials from the governing IRB in 
compliance with the provisions specified by [CONTACT_1622] (21 CFR Part 56) and other a pplicable 
regulatory agencies. Although Advanced Bi onics clinical research staff may assist with IRB 
applications, the Investiga tor is responsible for assuring compliance of the center‚Äôs 
respective IRB with applicable regulations  and any additional requirements imposed by [CONTACT_5040].  
A copy of the written IR B approval of the protocol, informed consent, IRB application 
materials, and recruitment advertising (if applicable) must be provided to Advanced Bionics 
prior to initiation of the study. The approval letter must be signed by [CONTACT_749255], specify the IRB name [CONTACT_3816], identify the clinical protocol by [CONTACT_29985] /or 
protocol number, and include the d ate that approval was granted. The Investigator is 
responsible for obtaining continued review of the clinical study at intervals not exceedin g 
one year or as otherwise speci fied by [CONTACT_1201]. The Investigator must provid e Advanced 
Bionics with written documentation of the review and materials submitted to the IRB for 
continuing approval .  
Investigators must notify the IRB promptly regarding all S AEs that occur at their site, in 
accordance with local reporting policy, and report other safety information provided by 
[CONTACT_749256].  
15.3 Documents and Records  
15.3.1  Pre-Study Documentation Requirements  
Prior to obtaining consent from any subjects, t he following documents are required:  
‚Ä¢ A copy of the Investigator Agreement, s igned and dated by [CONTACT_9532]  
‚Ä¢ A signed and dated copy of the Clinical Trial Agreement  
‚Ä¢ Financial Disclosure for the Principal Investigator [INVESTIGATOR_34511] -Investigator(s),  if 
applicable  
‚Ä¢ A copy of the written IRB approval of the protocol  
‚Ä¢ A copy of t he approved Informed Consent Form and written IRB approval of the 
form  
‚Ä¢ A copy of the signed and dated curriculum vitae of the Principal Investigator [INVESTIGATOR_749243]-Investigator(s), if a pplicable  
‚Ä¢ Copi[INVESTIGATOR_749244]  (surgeons and 
audiologists)  
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, [ADDRESS_1024630] Retention  
All study records (e.g., proto col, IRB correspondence and approvals, eCRFs, patient 
records, consent forms, reports) must be maintained for a minimum of [ADDRESS_1024631] approval of a marketing application in an International Conferenc e on 
Harmonization (ICH) region and until the re are no pending or contemplated 
marketing applications in an ICH region or until at least [ADDRESS_1024632] elapsed since 
the formal discontinuation of clinical development of the study intervention. These 
document s should be retained for a longer period, how ever, if required by [CONTACT_13125] . After this time records may be transferred to Advanced Bionics for 
indefinite storage.  
If an Investigator opts to discontinue participation in the study, all records will be 
transferred to a mutually agreed designee (i.e., another Investigator) . This transfer 
is subject to Advanced Bionics‚Äô approval and will be documented in writing with 
copi[INVESTIGATOR_749245] . If an Investigator leaves the site at which the study 
was conducted, Advanced Bionics shall be cont acted regarding the disposition of 
documents.  
15.3.[ADDRESS_1024633] is received 
from any regulatory or government agency. A copy of the audit findings if conducted 
should be forwarded to the study Sponsor following the conclusion of the visit.  
15.4 Stud y Audits  
Advanced Bionics‚Äô internal auditors or contract auditors may eval uate the conduct of the 
study. These parties will have access to all study -related documents . Advanced Bionics 
audit reports are confidential and proprietary.  
15.5 Stud y Funding  
The study  is funded by [CONTACT_749257] ; financial agreements with the participating 
centers are addressed in a separate agreement.  
  
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, [ADDRESS_1024634] of the 
Investigator. In either case, a formal amendment cannot be initiated until it has been 
approved by [CONTACT_749257], FDA, and the IRB.  
16.2 Protocol Dev iations  
A protocol deviation refers to a study -related activity that is not in compliance with the 
approved investigational plan/protocol such as an assessment or part thereof are completed 
incorrectly or omitted or a participant not returnin g at a defined  study in terval. Deviation 
events are to be reported accordingly on a protocol deviatio n report form in the Electronic 
Data Capture system . Deviations from the clinical protocol and protocol requirements 
including GCP guidelines will be reviewed and evalua ted on an  ongoing basis. Appropriate 
corrective actions wil l be implemented as necessary. Dependent on nature of deviation, the 
Investigator may be required to notify the IRB .  
16.[ADDRESS_1024635] the 
rights , safety , or well -being of subjects. Emergency deviations or modifications to the 
protocol may be initiated without Advanced Bionics or IRB approval (21 CFR 50.24) only in 
cases where an immediate apparent hazard to subjects must be avoided. Emergency 
deviations or modifications must be reported to Advanced Bionics and the IRB no later than 
24 hours after the emergency .  
17. Publication Policy  
This clinical study will be registered with clinicaltrials.gov and results will  be made publicly 
available.  
Advanced Bionics intends to publish the results of the clinical investigation in a peer reviewed 
journal. Authorship for the publication of the multi -center data will be jointly decided between 
Advanced Bionics and the Investig ators. Further details of the publication policy will be governed 
by [CONTACT_749258].  
18. Bibliography  
‚Ä¢ Gifford RG, Shallop JK, Peterson MA. (2008) Speech recognition materials and ceiling  effects: 
Considerations for cochlear implant programs. Audiol Neurotol 13:  263-271. 
‚Ä¢ Little RJA and Rubin  DB. (2002)  Statistical Analysis with Missing Data . Wiley  
‚Ä¢ Petrovcic A, Boot WR, Burnik T, Dolnicar V. (2019) Improving the Measurement of Older 
Adults'  Mobile Device Proficiency: Results and Implications from a Study of Older Adult 
Smartphone Users  
‚Ä¢ Roque NA and Boot WR. (2018) A New Tool for  Assessing Mobile Device  Proficiency in Older  
Adults: The Mobile  Device Proficiency  Questionnaire . Journal of Appli ed Gerontolog y 37(2) : 
131‚Äì156 
‚Ä¢ Rubinstein JT, Parkinson  WS, Tyler  RS, Gantz  BJ. (1999)  Residual speech recognition and 
cochlear implant performance: effects of implantation criteria . Am J Otol  20(4):445 -52. 
‚Ä¢ Spahr AJ, Dorman MF, Litvak LM, Van Wie S, Gifford  RH, Loizou PC, Loiselle LM, Oakes T, 
Cook S.  (2012)  Development and validation of the AzBio sentence lists. Ear Hear. 33(1):  112-
7.  
‚Ä¢ Tyler RS, Summerfield  QA. (1996)  Cochlear Implantation: Relationships with Research on 
Auditory Deprivation and Acclimatiz ation , Ear Hear  17(3):  38S-50S 
  
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System  
Version # 1. 2 / Version Date : May 26, [ADDRESS_1024636] the study as described in the protocol and in 
accordance with the relevant parts of the ICH Guidelines for GCP , ISO [ZIP_CODE], th e Declaration 
of Helsinki, and the pertinent individual country laws/regulations.  
 
In addition, I assume responsibility for protocol compliance for persons to whom I delegate 
study related tasks.  
 
Study Center:   _______________________________   
Principal Investigator [INVESTIGATOR_598605]:    _______________________________   
Principal Investigator [INVESTIGATOR_7496]:   _______________________________   
Signature [CONTACT_1782]:   _______________________________   
 
 